Stockreport

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2023

Enveric Biosciences, Inc.  (ENVB) 
PDF Product Development Highlights:Selected neuroplastogen lead candidate EB-003, a potential first-in-class therapeutic option for addressing difficult-to-treat mental heal [Read more]